Stockreport

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update [Yahoo! Finance]

Sonnet BioTherapeutics Holdings, Inc.  (SONN) 
PDF Announced early safety data from the company's Phase 1b/2a clinical trial of SON-080 in patients with chemotherapy-induced peripheral neuropathy (CIPN) Received $4.3 [Read more]